KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma
4 Views
administrator
07/12/23
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma.
-
Category
Show more
Facebook Comments
No comments found